Published on in Vol 22, No 7 (2020): July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/16904, first published .
Understanding the Acceptability of Subdermal Implants as a Possible New HIV Prevention Method: Multi-Stage Mixed Methods Study

Understanding the Acceptability of Subdermal Implants as a Possible New HIV Prevention Method: Multi-Stage Mixed Methods Study

Understanding the Acceptability of Subdermal Implants as a Possible New HIV Prevention Method: Multi-Stage Mixed Methods Study

Journals

  1. Chan C, Vaccher S, Fraser D, Grulich A, Holt M, Zablotska-Manos I, Prestage G, Bavinton B. Preferences for Current and Future PrEP Modalities Among PrEP-Experienced Gay and Bisexual Men in Australia. AIDS and Behavior 2022;26(1):88 View
  2. Thoueille P, Choong E, Cavassini M, Buclin T, Decosterd L. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. Journal of Antimicrobial Chemotherapy 2022;77(2):290 View
  3. Sued O, Nardi N, Spadaccini L. Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: a scoping review. Current Opinion in HIV and AIDS 2022;17(3):145 View
  4. Tagliaferri Rael C, Giguere R, Sutton S, Horn E, Schieffer R, Greene G, D'Aquila R, Bryndza Tfaily E, Kiser P, Hope T. Preferences Among Physicians and Men Who Have Sex with Men (MSM) for a Long-Acting, Removable Implant for HIV Prevention: A Discrete Choice Study. AIDS Research and Human Retroviruses 2022;38(12):898 View
  5. Matthews R, Zang X, Barrett S, Koynov A, Goodey A, Heimbach T, Weissler V, Leyssens C, Reynders T, Xu Z, Rottey S, Vargo R, Robertson M, Stoch S, Iwamoto M. A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial of Radiopaque Islatravir-Eluting Subdermal Implants for Pre-exposure Prophylaxis Against HIV-1 Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes 2023;92(4):310 View
  6. Huang Y, Tian R, Zhou Z, Xu J, Agins B, Zou H, Chen Q, Sun Z, Zhong Q, Ma Z, Jiang H. HIV Pre-Exposure Prophylaxis Use on a Global Scale Among Men Who Have Sex with Men: A Systematic Review and Meta-Analysis. AIDS Patient Care and STDs 2023;37(4):159 View
  7. Vora L, Sabri A, Naser Y, Himawan A, Hutton A, Anjani Q, Volpe-Zanutto F, Mishra D, Li M, Rodgers A, Paredes A, Larrañeta E, Thakur R, Donnelly R. Long-acting microneedle formulations. Advanced Drug Delivery Reviews 2023;201:115055 View
  8. Rogers B, Chan P, Sutten-Coats C, Zanowick-Marr A, Patel R, Mena L, Goedel W, Chu C, Silva E, Galipeau D, Arnold T, Gomillia C, Curoe K, Villalobos J, Underwood A, Sosnowy C, Nunn A. Perspectives on long-acting formulations of pre-exposure prophylaxis (PrEP) among men who have sex with men who are non-adherent to daily oral PrEP in the United States. BMC Public Health 2023;23(1) View
  9. Tagliaferri Rael C, Giguere R, Bryndza Tfaily E, Sutton S, Horn E, Schieffer R, Hendrix C, D’Aquila R, Hope T. The Global Impact of Diversifying PrEP Options: Results of an International Discrete Choice Experiment of Existing and Potential PrEP Strategies with Gay and Bisexual Men and Physicians. AIDS Research and Human Retroviruses 2024;40(10):591 View
  10. Rael C, Das D, Porter J, Lopez-Ríos J, Abascal E, Dolezal C, Vaughn M, Giffenig P, Lopez J, Stonbraker S, Sun C, Velasco R, Bitterfeld L, Bockting W, Bauermeister J. Provider Factors Likely to Impact Access and Uptake of Long-Acting Injectable Cabotegravir for Transgender Women in the United States: Results of a Qualitative Study. Journal of the Association of Nurses in AIDS Care 2024;35(5):437 View
  11. Huanbutta K, Puri V, Sharma A, Singh I, Sriamornsak P, Sangnim T. Rise of implantable drugs: A chronicle of breakthroughs in drug delivery systems. Saudi Pharmaceutical Journal 2024;32(12):102193 View